NCT00398411View on ClinicalTrials.gov

Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hodgkin DiseaseNon-Hodgkin LymphomaMultiple MyelomaBacteremia
Interventions
DRUG

moxifloxacin

400 mg p.o. per day

DRUG

placebo

one tablet per day p.o.

Trial Locations (1)

50924

Klinikum der Universität zu Köln, Cologne

All Listed Sponsors
lead

University of Cologne

OTHER

NCT00398411 - Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | Biotech Hunter | Biotech Hunter